DCT Advisors Approve $22 Mil. Set Aside For Interactive R01s Systemic Therapies
In Brief: NCI Awards 4 Contracts For Enrichment Program; Dana-Farber Names Breast Center Leadership
NIH Authorization Set For Another Try; Women’s Cancers Are Targeted
DCT Advisers Ok Expansion of Phase 1, Phase 2 Testing
More DCT Concepts Approved By Advisors
Taxotere Encouraging, CPT-11, Other Agents Entering Trials; Chabner
Procedures For Ending IGs Announced
Trending Stories
- How a Georgetown med school student found her calling in surgery, law, and health equity
- Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor
- Lei Zheng got his PhD in San Antonio; now he returns as cancer center director at Mays
- As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.” - Huiping Liu discusses mentorship, translational research on the UChicago Cancer Luminaries podcast